15 results about "Inflammatory pathways" patented technology

This invention relates to the field of medical information management technology, including an AI-based endometriosis management system. The system comprises a thickness dynamic monitoring module, an inflammation level assessment module, a lesion spread analysis module, a periodic lesion tracking module, and a disease progression analysis module. In this invention, AI is used to segment ultrasound image data, enabling dynamic monitoring of lesion areas. Lesion boundaries are extracted, and changes in local inflammatory marker concentrations are calculated, making the screening of abnormal inflammatory areas more accurate and enabling early identification of lesion development. The tracking of periodic lesions, combined with analysis of lesion contour changes and area increases / decreases, enhances the quantitative control of disease progression. The future development trend of lesions, combined with the calculation of periodic inflammatory pathways, makes the prediction of disease evolution more consistent with physiological changes. Multi-dimensional lesion analysis combined with AI intelligent calculation expands the diagnosis and treatment of endometriosis from static assessment to dynamic trend prediction, improving the adaptability of personalized treatment plans.

This invention relates to the field of bioactive peptide preparation technology, and discloses a method for preparing and applying a bifunctional antioxidant and anti-inflammatory peptide based on porcine skin collagen. The bifunctional peptide has the amino acid sequence GPSGPPGEKGP. Through peptidomics and computer simulation screening, this invention identified five novel antioxidant peptides with good solubility, non-sensitizing properties, and non-toxicity. Using an AFB1-induced HuH7 cell oxidative damage model, in in vitro cell experiments, GP-11 was shown to significantly reduce ALT, AST activity, and ROS levels, enhance the activity of SOD, CAT, and GSH-Px antioxidant enzymes, and activate the Keap1-Nrf2 pathway. It also reduced the levels of inflammatory factors TNF-α and IL-6 by downregulating the classical cGAS-STING inflammatory pathway. GP-11 exhibits both significant antioxidant effects and the ability to reduce the levels of inflammatory factors, demonstrating a dual function of antioxidation and anti-inflammation.

This invention discloses the application of berberine-loaded herbal carbon dots in the preparation of drugs for treating ulcerative colitis. The BLCDs of this invention exert their therapeutic effect through a dual synergistic mechanism: directly scavenging reactive oxygen species through surface oxygen-containing functional groups, and simultaneously inhibiting the NLRP3 inflammatory pathway and downstream pro-inflammatory factors by promoting IL-10 expression. In a DSS-induced ulcerative colitis mouse model, BLCDs showed superior efficacy compared to the positive control drug 5-ASA and its single component, significantly improving intestinal inflammation, oxidative stress, and barrier dysfunction. Their therapeutic advantage stems from the intestinal retention effect conferred by their larger particle size, as well as their regulatory effects on intestinal flora and metabolites, particularly by inhibiting Klebsiella to reduce TMAO production, thereby activating the multi-cascade regulatory network of IL-10.

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.

The present invention relates to a composition for preventing or treating neuroinflammation, comprising, as an active ingredient, an extract of the aerial parts of Peucedanum japonicum. The extract of the aerial parts of Peucedanum japonicum and a compound isolated therefrom, of the present invention, were confirmed to inhibit NO production in microglial cell lines in which inflammatory responses are induced by LPS. It was also confirmed that the extract of the aerial parts of Peucedanum japonicum inhibited various inflammatory pathways related to neuroinflammation, and inhibited inflammatory activation factors. Furthermore, the extract was confirmed to inhibit the expression of inflammatory proteins in neuroinflammatory responses, thereby confirming the anti-neuroinflammatory effect thereof.

This invention discloses a multi-drug composition for the treatment of ankylosing spondylitis. For the first time, this invention addresses the etiology of streptococcus-related diseases by proposing a synergistic treatment strategy combining a classic tumor necrosis factor antagonist (such as etanercept) with a narrow-spectrum antibiotic (benzathine penicillin). This approach breaks through the traditional treatment strategy that targets only the inflammatory pathway, providing a novel entry point for AS treatment.

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

The application discloses a kind of lipid molecules for nucleic acid delivery and liver microenvironment repair and application, belong to medical biotechnology field, and the lipid molecule is the compound shown in formula (1) or its pharmaceutically acceptable salt, it contains tocopherol or tocol trienol fragment and zinc ion coordination group in its structure, with the chemical and biological function of ionizable lipid and the antioxidant, anti-inflammatory activity of vitamin E and zinc.The lipid nanoparticle comprising the compound can efficiently deliver various nucleic acids, and while releasing in liver target, by eliminating active oxygen, inhibiting inflammatory pathways, actively improving liver microenvironment, reducing oxidative stress and fibrosis damage.The delivery system realizes the synergistic treatment concept of "carrier is medicine", and has wide application prospect in nucleic acid drug treatment and gene vaccine development in chronic liver disease, liver fibrosis, liver cancer and other diseases.

The application belongs to the technical field of biological medicine, and discloses application of oridonin in preparation of a medicine for treating rheumatoid arthritis synovitis. For the first time, it is confirmed that oridonin takes glyceraldehyde-3-phosphate dehydrogenase as a direct action target, covalently combines through an α, β-unsaturated ketone, inhibits enzyme activity, blocks abnormal glycolysis of rheumatoid arthritis synovial cells, activates a KEAP1-NRF2 / HO-1 antioxidant anti-inflammatory pathway, inhibits an NF-κB inflammatory signal, and intervenes in a pathological process of rheumatoid arthritis synovitis from multiple dimensions, thereby providing a scientific basis for clinical application and deep development of oridonin against RA synovitis. A medicine composition containing oridonin and application of the medicine composition in preparation of an anti-rheumatoid arthritis synovitis medicine are disclosed. The application has advantages of target point precision, remarkable curative effect, high safety, mechanism innovation and the like, and provides a brand-new scheme for clinical treatment of rheumatoid arthritis synovitis.

This invention discloses a multilayer microsphere for the prevention and / or treatment of bacterial diarrhea, its preparation method, and its applications, relating to the field of biomedical technology. The multilayer microsphere has a three-layer core-shell structure: the core layer is loaded with *Lactobacillus plantarum* and sodium butyrate, the middle layer is a chitosan coating layer, and the outer layer is a sodium alginate coating layer. This invention has found that *Lactobacillus plantarum* and sodium butyrate have a significant synergistic antibacterial effect, effectively inhibiting the proliferation of pathogenic *Escherichia coli* and *Salmonella*. In vivo experiments have confirmed that the multilayer microsphere can effectively restore the body weight of diarrhea-prone animals, repair pathological damage to the jejunum and colon, and alleviate intestinal inflammation at the molecular level by inhibiting the activation of NF-κB and MAPK inflammatory pathways, downregulating the expression of pro-inflammatory factors IL-1β, IL-6, and TNF-α, and upregulating the level of the anti-inflammatory factor IL-10. The multilayer microsphere provided by this invention can serve as a novel, green, and safe formulation suitable for the prevention and control of bacterial diarrhea in livestock and poultry farming.

The application discloses a recombinant lactobacillus casei expressing sialyltransferase ST6GALNAC1, and belongs to the field of genetic engineering and microbial technology. The recombinant bacterium is obtained by cloning the ST6GALNAC1 gene into a pPG612 vector and electrotransforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucus protein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammatory pathway, and regulate intestinal flora structure, thereby effectively relieving intestinal injury and systemic inflammatory response caused by salmonella. The application provides a strain basis and technical support for development of a new type of oral microecological preparation.

The present application relates to the technical field of pharmaceutical preparation, and discloses a kind of quenching medicine composition for alcohol by regulating liver inflammation through NF-κB channel, including core active monomer consisting of quercetin, kaempferol and aloe emodin, HPMCAS-HF type skeleton network polymer, L-arginine, poloxamer 188, and by PEG 400 and deionized water composition transient mass transfer fluid, each raw material is made into amorphous powder by hot melt extrusion reaction through co-rotating twin-screw extruder.The processing temperature is reduced by the aid of transient mass transfer fluid plasticizing, and the degradation of active monomer by heat is avoided;The monomer is stabilized in amorphous form by polymer skeleton, and the local dissolution microenvironment is adjusted by L-arginine, which overcomes the defect of poor water solubility of natural monomer.The present application improves the dissolution and bioavailability of the drug, so that multiple components synergistically inhibit the NF-κB inflammatory pathway, and enhance the effect of quenching liver.

The present disclosure relates, in part, to methods of treating fibrotic and inflammatory, diseases with stromal remodeling, and proliferative diseases such as fibrotic diseases and cancer. Specifically, the disclosure relates to compositions for inhibiting the expression of genes, or the proteins they encode, that are involved in fibrotic and / or inflammatory pathways. The disclosure specifically teaches compounds for inhibiting the expression of the ABHD14B gene, either independently or in combination with compounds that inhibit CB1R and / or MGLUR5. Specific antisense oligonucleotides including siRNAs and gapmers for inhibiting ABHD14B gene expression are disclosed. Also disclosed are method of treating individuals using the disclosed compounds as well as kits comprising the disclosed compounds.

The anti-inflammatory composition may be administered to a subject in need thereof to prevent or reduce inflammation, including inflammation resulting from asthma. The anti-inflammatory composition may comprise both onion bulb extract and one or more glucocorticosteroids, particularly a low-dose glucocorticosteroid. The anti-inflammatory composition may be administered to a subject at risk of developing asthma to prevent the progression of asthma. The anti-inflammatory composition may act by reducing pEGFR levels, or by inhibiting other inflammatory pathways.

The present application relates to a skin cell soothing and repairing composition containing artemisia and its preparation method and application, and belongs to the technical field of cosmetics. The present application finds that only by inhibiting the upstream anti-inflammatory pathway of the NF-kappa B pathway, the anti-inflammatory effect is limited, while inhibiting the NF-kappa B pathway, the downstream transmission chain is blocked, and the anti-inflammatory effect is significantly enhanced. Based on this, the present application inhibits the upstream anti-inflammatory pathway by artemisia extract and jasminum officinale extract, reduces the recruitment and infiltration of inflammatory cells, blocks the downstream transmission chain, and synergistically improves the anti-inflammatory effect. In addition, the present application cooperates oat kernel oil, jasmine flower oil and squalane, on the one hand, improves the solubility of fat-soluble active substances, on the other hand, participates in the repair, stabilization and optimization of the lipid structure of the skin cuticle, synchronously opens the skin fat-soluble channel, and more efficiently transports active substances, thereby realizing excellent soothing, repairing and stabilizing effects.